SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of silicon nitride ceramic for medical and non-medical applications, announced today multiple U.S. and international patent applications for development of new technologies utilizing the Company’s silicon nitride.
The following expand on several existing antipathogenic and coating-technology patent applications:
- Systems and Methods for Rapid Inactivation of SARS-CoV-2 by Silicon Nitride, Copper and Aluminum Nitride
- Antipathogenic Composites and Devices and Methods of Use Thereof
- Antipathogenic Face Mask
- Systems and Methods for Physical Vapor Deposition of Silicon Nitride Coatings Having Antimicrobial and Osteogenic Enhancements
- Methods of Silicon Nitride Laser Cladding
Methods for Laser Coating of Silicon Nitride on a Metal Substrate
The patent applications largely relate to the development of antipathogenic and/or osteogenic composite systems, methods, devices, and surface coatings. The technologies can be applied in antipathogenic devices such as face masks and filters, or in medical devices such as orthopedic, wound care dressings, and dental implants. The patent applications are an important milestone in SINTX’s commitment to leverage the inherent antipathogenic and osteogenic properties of silicon nitride in powders and coatings to address viral diseases such as COVID-19 and to improve outcomes in medical device implantations.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 13485:2016 certified, and ASD9100D certified manufacturing facility.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: the patent applications may not be granted or may not afford the protection we are seeking; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Source:-https://finance.yahoo.com/news/sintx-technologies-files-multiple-u-130000864.html
